

### Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immunoncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation of Dexmedetomidine in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immunoncology agents.

### BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

Nov 13 2020, 7:00 AM EST

### BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 12 2020, 7:00 AM EST

### BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders

Nov 11 2020, 7:00 AM EST

### Stock Overview

|            |                  |
|------------|------------------|
| Symbol     | BTAI             |
| Exchange   | Nasdaq           |
| Market Cap | 1.11b            |
| Last Price | \$45.70          |
| 52-Week    | \$5.58 - \$71.50 |

12/04/2020 04:00 PM EST

### Investor Relations

|  |
|--|
| Solebury Trout   |
| John Graziano  |
| T: 1.646.378.2942  |
| <a href="mailto:jgraziano@troutgroup.com">jgraziano@troutgroup.com</a> |

### Management Team

#### Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

#### Frank D. Yocca, Ph.D.

Chief Scientific Officer

#### Vincent J.O'Neill M.D.

Senior Vice President & Chief Medical Officer

#### Reina Benabou, M.D., Ph.D.

Senior Vice President & Chief Development Officer

#### Chetan Lathia Ph.D.

Senior Vice President and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs

#### Richard I. Steinhart

Chief Financial Officer & Vice President

#### William P. Kane

Chief Commercial Officer

---

### BioXcel Therapeutics, Inc.

555 Long Wharf Drive  
12th Floor  
New Haven, CT 06511  
United States

---

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.